SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the ...

A study showed cholesterol-lowering statins do not significantly affect ALS progression or survival. Statin prescriptions for ALS patients should be based on metabolic needs, not ALS diagnosis. More ...

Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc analysis of ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

With the help of artificial intelligence, a coalition of Bay Area institutions identified 18 FDA-approved drugs that could improve the lives of those suffering from amyotrophic lateral sclerosis, ...

For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant medication is associated with a trend toward survival benefit, according to a ...

Patients with ALS, or Lou Gehrig's disease, live an average of only three years after symptoms begin, though some can survive closer to 10 years. What drives these differences in survival has remained ...

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests. ALS is a ...